|
Sign In to gain access to subscriptions and/or personal tools.
|
SMN Transcript Stability: Could Modulation of Messenger RNA Degradation Provide a Novel Therapy for Spinal Muscular Atrophy?
Christopher R. Heier, BS
Department of Pediatrics, Feinberg School of Medicine, Northwestern University, and the Human Molecular Genetics Program, Children's Memorial Research Center, Chicago, Illinois
Rocky G. Gogliotti, BS
Department of Pediatrics, Feinberg School of Medicine, Northwestern University, and the Human Molecular Genetics Program, Children's Memorial Research Center, Chicago, Illinois
Christine J. DiDonato, PhD
Department of Pediatrics, Feinberg School of Medicine, Northwestern University, and the Human Molecular Genetics Program, Children's Memorial Research Center, Chicago, Illinois, c-didonato{at}northwestern.edu
Proximal spinal muscular atrophy is caused by deletion or mutation of the survival motor neuron 1 gene, SMN1. Rentention of a nearly identical copy gene, SMN2, enables survival but is unable to fully compensate for the loss of SMN1. The SMN1 and SMN2 genes differ by a single nucleotide that results in alternative splicing of SMN2 exon 7 due to the disruption of a binding site for an essential splicing factor. This alternatively spliced form encodes a partially functional truncated protein. Because SMN2 is present in patients with spinal muscular atrophy, it is an ideal therapeutic target. Some of the current approaches to increase SMN protein levels are aimed at increasing the transcription from SMN2 or at preventing exon 7 skipping. One area that has yet to be investigated is the stability of messenger ribonucleic acid (RNA) transcripts produced from SMN2. We postulated that transcripts derived from SMN2 may be less stable because alternative splicing, recruitment of RNA-binding proteins, and alteration of stop codons have been associated with changes in rates of messenger RNA decay; these features are all characteristic of SMN2. Accordingly, transcript degradation was examined within primary fibroblast cells that exclusively contained SMN1 or SMN2 by treating cultures with a transcriptional inhibitor to observe messenger RNA stability. The results indicate that SMN transcript instability does not play a role in the disease mechanism, suggesting that therapeutic modulation of messenger RNA degradation would not target a molecular defect in patients with spinal muscular atrophy, although it could provide general benefits by increasing total pools of SMN2 transcripts.
Key Words: spinal muscular atrophy • SMN1 gene • SMN2 gene
References
- Crawford TO, Pardo CA The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. 1996;3(2):97-110.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Rochette CF, Gilbert N., Simard LR SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens. Hum Genet. 2001;108(3): 255-266.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lefebvre S., Burglen L., Reboullet S., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155-165.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15(3):228-237.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lorson CL, Hahnen E., Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96(11):6307-6311.[Abstract/Free Full Text]
- Cartegni L., Hastings ML, Calarco JA, et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet. 2006;78(1):63-77.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Cartegni L., Krainer AR Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002;30(4):377-384.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Lorson CL, Androphy EJ An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet. 2000;9(2):259-265.[Abstract/Free Full Text]
- Lorson CL, Strasswimmer J., Yao JM, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity [letter]. Nat Genet. 1998;19(1):63-66.[Web of Science][Medline]
[Order article via Infotrieve]
- Coovert DD, Le TT, McAndrew PE, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet. 1997;6(8):1205-1214.[Abstract/Free Full Text]
- Feldkotter M., Schwarzer V., Wirth R., et al. Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2): 358-368.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hsieh-Li HM, Chang JG, Jong YJ, et al. A mouse model for spinal muscular atrophy. Nat Genet. 2000;24(1):66-70.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- McAndrew PE, Parsons DW, Simard LR, et al. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet. 1997; 60(6):1411-1422.[Web of Science][Medline]
[Order article via Infotrieve]
- Sumner CJ Therapeutics development for spinal muscular atrophy. NeuroRx. 2006;3(2):235-245.[CrossRef][Medline]
[Order article via Infotrieve]
- Caceres JF, Screaton GR, Krainer AR A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev. 1998;12(1):55-66.[Abstract/Free Full Text]
- Lemaire R., Prasad J., Kashima T., et al. Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins. Genes Dev. 2002;16(5):594-607.[Abstract/Free Full Text]
- Thiele A., Nagamine Y., Hauschildt S., Clevers H. AU-rich elements and alternative splicing in the ß-catenin 3'UTR can influence the human ß-catenin mRNA stability. Exp Cell Res. 2006;312(12):2367-2378.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Vela E., Roca X., Isamat M. Identification of novel splice variants of the human CD44 gene. Biochem Biophys Res Commun. 2006;343(1):167-170.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Grellscheid SN, Smith CW An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon. Mol Cell Biol. 2006;26(6):2237-2246.[Abstract/Free Full Text]
- Le Hir H., Gatfield D., Izaurralde E., Moore MJ The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. EMBO J. 2001;20(17):4987-4997.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Reed R. Coupling transcription, splicing and mRNA export. Curr Opin Cell Biol. 2003;15(3):326-331.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Culbertson MR, Neeno-Eckwall E. Transcript selection and the recruitment of mRNA decay factors for NMD in Saccharomyces cerevisiae. RNA. 2005;11(9):1333-1339.[Abstract/Free Full Text]
- He F., Li X., Spatrick P., et al. Genome-wide analysis of mRNAs regulated by the nonsense-mediated and 5' to 3' mRNA decay pathways in yeast. Mol Cell. 2003;12(6):1439-1452.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Eberhardt W., Doller A., Akool ES, Pfeilschifter J. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther. 2007;114(1):56-73.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mifflin RC, Saada JI, Di Mari JF, et al. Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004;65(2):470-478.[Abstract/Free Full Text]
- Tong X., Van Dross RT, Abu-Yousif A., et al. Apigenin prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA stabilization and translational inhibition. Mol Cell Biol. 2007; 27(1):283-296.[Abstract/Free Full Text]
- Lai WS, Parker JS, Grissom SF, et al. Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts. Mol Cell Biol. 2006; 26(24):9196-9208.[Abstract/Free Full Text]
- Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54(5):647-654.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Andreassi C., Angelozzi C., Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet. 2004;12(1):59-65.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Livak KJ, Schmittgen TD Analysis of relative gene expression data using real-time quantitative PCR and the 2–
 CT Method. Methods. 2001;25(4):402-408.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve] - Gennarelli M., Lucarelli M., Capon F., et al. Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun. 1995;213(1):342-348.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Poulalhon N., Farge D., Roos N., et al. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin: a direct role as an antifibrotic agent? J Biol Chem. 2006;281(44):33045-33052.[Abstract/Free Full Text]
- Frugier T., Tiziano FD, Cifuentes-Diaz C., et al. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2000;9(5):849-858.[Abstract/Free Full Text]
- Le TT, Pham LT, Butchbach ME, et al. SMN7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet. 2005;14(6):845-857.[Abstract/Free Full Text]
- Mattis VB, Rai R., Wang J., et al. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet. 2006;120(4):589-601.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wolstencroft EC, Mattis V., Bajer AA, et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet. 2005;14(9):1199-1210.[Abstract/Free Full Text]
Journal of Child Neurology, Vol. 22, No. 8,
1013-1018 (2007)
DOI: 10.1177/0883073807305669
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R. A. Brumback
Child Neurologists Should Be Interested In Brain Tumors!
J Child Neurol,
November 1, 2009;
24(11):
1338 - 1340.
[PDF]
|
|
|
|
|
|
|
L. Garbes, M. Riessland, I. Holker, R. Heller, J. Hauke, C. Trankle, R. Coras, I. Blumcke, E. Hahnen, and B. Wirth
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate
Hum. Mol. Genet.,
October 1, 2009;
18(19):
3645 - 3658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. R. Heier and C. J. DiDonato
Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo
Hum. Mol. Genet.,
April 1, 2009;
18(7):
1310 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Sharova, A. A. Sharov, T. Nedorezov, Y. Piao, N. Shaik, and M. S.H. Ko
Database for mRNA Half-Life of 19 977 Genes Obtained by DNA Microarray Analysis of Pluripotent and Differentiating Mouse Embryonic Stem Cells
DNA Res,
February 1, 2009;
16(1):
45 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
